With over 500 individual compounds, the Amaryllidaceae alkaloids represent a large and structurally diverse group of phytochemicals. Coupled to this structural diversity is the significant array of biological properties manifested by many of its members, of which their relevance in motor neuron disease and cancer chemotherapy has attracted considerable attention. To this extent, galanthamine has evolved into a successful commercial drug for Alzheimer's disease since its approval by the FDA in 2001. Concurrently, there have been several positive indicators for the emergence of an anticancer drug from the Amaryllidaceae due to the potency of several of its representatives as cell line specific antiproliferative agents. In this regard, the phenanthridones such as pancratistatin and narciclasine have offered most promise since their advancement into clinical trials, following which there has been renewed interest in the cytotoxic properties of these alkaloids. Given this background, this review seeks to highlight the various mechanisms which have been invoked to corroborate the cytotoxic effects of Amaryllidaceae alkaloids.
The monocotyledonous plant family Amaryllidaceae comprises around 1000 species which are distributed through both tropical and subtropical regions of the globe, with a notable bio-geographical representation in Andean South America, the Mediterranean basin and southern Africa [1a,b] . These bulbous flowering plants are of considerable interest commercially due to their coveted horticultural and ornamental characteristics [1a,b] . The Amaryllidaceae is also recognized for its widespread application in the traditional medicine endemic to the various regions of its prominence [2] . For example, the research and development of galanthamine into a reputable Alzheimer's drug evolved out of the traditional usage of Galanthus species in the Caucasus region of Eastern Europe [3] .
The search for the chemical entities responsible for the biological activities of Amaryllidaceae plants led to the identification of its alkaloid constituents which have since come to be a distinguishing feature of the family [2b,4] . These are now represented by three major groups (lycorine 1, crinine 2 and galanthamine 3), three minor groups (tazettine 4, homolycorine 5 and montanine 6) as well as less-conspicuous congeners such as cherylline (7), trisphaeridine (8) and ismine (9) (Scheme 1) [2b,4] . All of these alkaloids are related via their common biogenetic precursor norbelladine (10) [2b,4] . The use of the Amaryllidaceae in the traditional remediation of cancer is known from the three regions of its provenance, with over thirty plants in eleven genera exploited for such purposes [2] . Interestingly, it has been established that the "father of medicine" Hippocrates had recognized the anticancer properties of Narcissus poeticus in recommending 'narcissus oil' for uterine tumors [5a] . Despite this history, it is only the latter part of the twentieth century which has seen an escalation in interest in the Amaryllidaceae alkaloids as viable chemotherapeutic agents [5] . Although cytotoxic effects have been observed across all structural groups of the Amaryllidaceae, it is the potency of the lycorane and crinane groups which have propelled them into the spotlight in both research and pharmaceutical platforms [5] . To date over 300 of such alkaloids have been subjected to screening programs utilizing various cancer cells, the most promising of which reside with the phenanthridones such as pancratistatin (11) and narciclasine (12) of the lycorine series [5] .
These polyhydroxy-functionalized structures display the requisite pharmacological characteristics, including high potency, selectivity and tolerability as well as low toxicity, which have sparked considerable interest in the clinical arena to promote their accelerated development [5] . As a consolidation of diverse studies focused on the antiproliferative properties of Amaryllidaceae alkaloids, we here examine the mechanisms which have been elucidated to explain these effects.
A landmark achievement in the field was the isolation of lycorine (1) from Narcissus pseudonarcissus in 1877 as the first alkaloid of the Amaryllidaceae [6a] , followed by its structure elucidation several decades later in 1956 [6b] . Intriguingly, the antiproliferative effects of lycorine in several cancer cell lines have been known since the 1920s [6c]. However, it was in plant systems that the cell growth inhibitory effects of Amaryllidaceae alkaloids largely came to the fore. Initially, Yamaguchi and Suda (1952) examined the germination and growth inhibitory effects of lycorine (1) on the broad bean Vicia faba and showed that its physiological effects were mediated through its action on cell division, including inhibition of the metaphase stage of mitosis and chromosomal aberration [7a] . Following these findings, De Leo et al. (1973) showed that lycorine was a strong growth inhibitor in higher plants and yeasts and that its effect was, by contrast, related to an increase in the number of cells in the interphase stage of cell division [7b] . In addition, lycorine was capable of inhibiting cell elongation in oat coleoptiles and pea segments, leading to the conclusion that it could affect protein synthesis or nucleic acid metabolism [7b] . Furthermore, lycorine effected a decrease in 14 C-leucine and 3 Huridine incorporation into protein and RNA, respectively, in some higher plant species and yeasts [7c] . In a cell-free system, lycorine showed no inhibitory effect on polypeptide chain elongation in yeast ribosomes implying that its growth inhibitory effects were manifested via protein synthesis inhibition, but not at the chain elongation step [7c] . Similarly, the first description of narciclasine (12), a phenanthridone of the lycorine series, by Ceriotti in 1967 
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Natural Product Communications Vol. 10 (1) 2015 173 was that of an antimitotic substance with significant growth inhibitory effects in wheat radicles at dosages as low as 0.05 g/mL [7d] . Given that lycorine (1) is a powerful inhibitor of ascorbic acid (AA) biosynthesis in plants [7b,c,e] , and since proliferating cells require large amounts of AA, lycorine-induced decrease in AA levels was observed to have a profound inhibitory effect on cell division in onion and broad bean seedlings [7f]. Such treatments produced marked arrest at the G 1 and G 2 phases of the cell cycle, with over 90% of cells accumulating in the G 1 phase [7f]. From these results, it was suggested that the role of AA in the cell cycle may be related to the control of the synthesis of hydroxyprolinecontaining proteins which play a pivotal role in the progression of the G 1 and G 2 phases [7f] .
Studies in the 1970s on the mechanism of action behind these effects focused mainly on the interaction of Amaryllidaceae alkaloids with eukaryote ribosomes [8] . Initially, it was shown that narciclasine (12) inhibited protein synthesis in rabbit reticulocytes and yeast cell-free systems by blocking peptide bond formation at the ribosome level, similar to anisomycin and trichodermin [8a] . Furthermore, resistance to narciclasine by the mutant TR 1 strain of Saccharomyces cerevisiae, which is anisomycin and trichodermin resistant, is due to an alteration on the peptidyl transferase centre of the 60S ribosomal unit [8b] . Several other Amaryllidaceae alkaloids, including lycorine (1), pseudolycorine (13), haemanthamine (14) and pretazettine (15), were also capable of inhibiting the peptide bond formation step of protein synthesis catalyzed by eukaryotic ribosomes [8c]. Interestingly, narciclasine, haemanthamine and pretazettine were shown to have a common binding site on the peptidyl transferase centre of the 60S ribosomal unit, different from that for lycorine and pseudolycorine [8c]. Furthermore, several alkaloids, including lycorine, pseudolycorine, dihydrolycorine, haemanthamine and pretazettine, were able to interfere with the binding of [ 3 H]narciclasine to yeast ribosomes, suggesting that there was an overlap of their respective binding sites [8d]. Apart from this, lycorine also inhibited the binding of CACCA-LeuAc to the donor site of the peptidyl transferase center of wheat-germ ribosomes [8e]. Lycorine (1), narciclasine (12), pseudolycorine (13), haemanthamine (14), pretazettine (15) and dihydrolycorine (16) at concentrations of 0.1 mM and lower were able to halt the growth of human cervical adenocarcinoma (HeLa) cells as described by Jimenez et al. (1976) [8f] . Furthermore, at their growth inhibitory concentrations, all of these alkaloids blocked protein synthesis in S-180 ascites tumors and stabilized HeLa cell polysomes in vivo, indicating that they halt protein synthesis in eukaryote cells by inhibiting the peptide bond formation step [8f]. In addition to this, lycorine inhibited [ 3 H]leucine incorporation into poliovirus infected HeLa (human cervical adenocarcinoma) cells in a dose-dependent manner, although it did not completely inhibit translation [8g] . As such, the viral proteins were identified as derived from the P1 (5' terminus), P2 (middle) or P3 (3' terminus) region of the poliovirus translation unit, suggesting that lycorine may act at the termination level [8g]. Furthermore, lycorine (1) reduced the cytopathic effect of enterovirus 71 (EV71) in human rhabdomyosarcoma (RD) cells by inhibiting replication via blockage of the elongation of the viral polyprotein during translation [8h]. Apart from this, it has been suggested that the cytotoxicity of lycorine (1), pseudolycorine (13) and 2-Oacetylpseudolycorine (17) (Scheme 1) on mouse LMTK fibroblasts (ED 50 s 0.3-0.6 g/mL) was due to the effect of these alkaloids on the protein of the cytoskeleton which is in abundance in these cells [8i] . Further studies by Rodriguez-Fonseca et al. (1995) were directed at the ribosomal binding sites of known peptidyl transferase inhibitors, including several antibiotics (such as anisomycin and chloramphenicol amongst others) as well as narciclasine (12) [8j]. These compounds exhibited varying degrees of specificity for bacterial, archaeal and eukaryotic ribosomes despite a high level of conservation in the sequence and secondary structure of the peptidyl transferase centre of the 23S-like rRNAs [8j] . Binding experiments revealed that they effected changes which ranged from one or two nucleotides (for anthelmycin and narciclasine) to eight or nine (virginiamycin M 1 ), from which it was inferred that these compounds are capable of inducing and stabilizing a particular functional conformer of the peptidyl transferase center [8j].
The first direct evidence for the antiproliferative effects of Amaryllidaceae alkaloids against cancer cells was provided by Ceriotti (1967) whereby narciclasine (12) exhibited a pronounced antimitotic effect in S-180 ascites tumors in mice [7d]. Through intraperitoneal (or subcutaneous) injection and oral administration at low dosages a drastic decline in the number of mitoses was observed after 2 hours, with an LD 50 established at 6 mg/kg [7d]. It was suggested from these results that narciclasine was a metaphasic or preprophasic "poison" with mitoclasic activity at high dosages [7d].
Guided by these findings, there was significant interest during the early 1970s in the cytotoxic effects of pseudolycorine (13) and an unidentified alkaloid isolated from Narcissus tazetta [9] . Initially, both alkaloids displayed a remarkable prolongation of lifespan in Rauscher virus-infected leukemic mice when compared with standard leukemia drugs, such as cyclophosphamide, vincristine sulfate and mercaptopurine [9a] . Furthermore, pseudolycorine suppressed the development of splenomegaly and increase in nucleated blood cells, and produced a drop in plasma viral titer without apparent toxic effects [9a] . A combination of either of these alkaloids with cyclophosphamide or mercaptopurine drastically enhanced their efficacy in Rauscher leukemia mice compared with the administration of either drug singly [9b]. In addition, the alkaloids did not impair humoral antibody production in the leukemic mice compared with the standard drugs which were in this case immunosuppressive during long-term administration, neither did they suppress interferon induction by the polyriboinosinicpolyribocytidylic acid complex [9b] . Further studies revealed that the residual alkaloid from Narcissus tazetta inhibited the activity of RNA-dependent DNA polymerase (reverse transcriptase), which is associated with various oncogenic RNA viruses [9c]. The alkaloid is peculiar in its activity since it appears to bind to the enzyme itself rather than interacting with the nucleic acid template [9c].
The interaction and influence of Amaryllidaceae alkaloids on cellular DNA is an integral step in the manifestation of their biological effects [10] . For example, the lycorine variant hippadine (18) in its reversible inhibition of fertility in male rats was shown to produce a significant decrease in testicular DNA, accompanied by an increase in protein content [10a] . Furthermore, the cytotoxic effects of 6-hydroxybuphanisine (19) and pratorinine (20) on human T-lymphoma (Molt4) cells was shown to involve the incorporation of [ 3 H]thymidine [10b]. Apart from this, Schmeda-Hirschmann et al. (2000) studied the interaction of a library of Amaryllidaceae alkaloids with calf thymus DNA and in the process revealed the remarkable binding coefficients of tazettine (4) (99.1%), pseudolycorine (13) (99.7%), haemanthamine (14) (99.6%) and 8-O-demethylhomolycorine (21) (100%), which were comparable with that of vinblastine (98.2%) at the same tested concentration of 0.5 mg/mL [10c] . Lycorine has been shown to be a weak DNA-damaging agent based on its low toxicity towards Saccharomyces cerevisiae strain Y321 [10d]. However, it has been shown that lycorine (1), haemanthamine (14) and haemanthidine Nair et al.
(22) (Scheme 1) do not bind to calf thymus DNA via intercalation in consequence of their non-planar structures [10e]. By contrast, lycorine and haemanthamine were capable of intercalation with the flexible double-stranded fragments of Saccharomyces tRNA, which was used to explain their potent antiproliferative effects against both parental and multi-drug resistant forms of L5178 mouse lymphoma (IC 50 s 0.250.3 g/mL) [10e]. The interaction of lycorine with calf thymus double-and single-stranded DNA has been measured electrochemically utilizing differential pulse voltammetry (DPV) based on the oxidation signals of guanine and adenine [10f].
Permeability and solubility are essential criteria in establishing the efficacy of a drug candidate [11a] . Maximum drug absorption occurs when a drug has maximum permeability and maximum concentration (saturation solubility) at the site of absorption [11a] . Permeability across biological membranes is a key factor in the absorption and distribution of drugs [11a] . Poor permeability can arise through a number of structural features and membrane-based efflux mechanisms [11a] . It can lead to poor absorption across the gastrointestinal mucosa or poor distribution throughout the body [11a] . As such, these factors have been given serious consideration in the pharmacological development of the Amaryllidaceae alkaloid pancratistatin (11) in the cancer arena [11b]. For example, the solubility of pancratistatin has been improved to around the 1 mg/mL mark through the use of complexing agents such as either nicotinamide or cyclodextrin [11b] . Other approaches to circumvent the notoriously poor solubility of pancratistatin involved its functionalization to phosphate pro-drugs [11c,d] . In attempts to enhance the lipophilicity of lycorine (1), it was demonstrated that pre-complexation with oleic acid followed by mannosylated nanoemulsion formulation had a notable effect both on the uptake of the drug as well as its growth inhibition of A549 human lung carcinoma cells [11e] . Other studies showed that hippadine (18) potentiated the viability of S-180 ascites tumor cells by membrane stabilization, which was suggested to be mediated via complexation with various steroidal entities [11f]. Furthermore, Dasari et al. (2014) uncovered that there was a pronounced lipophilic effect in the cytotoxicity of an extensive library of synthetically-derived lycorine analogs, highlighting the importance of cell permeability in this activity [11g] . For example, the silyl lycorine ether (23) (Scheme 1) was several orders of magnitude more potent than the positional methyl ethers (24 and 25) in a screen involving five different cancer cell lines [5c,11g] . Conversely, the superior activity of lycorine, being the exception in this case, was suggested to relate to it being a suitable hydrophilic substrate for active cellular transport systems involved in the shuttling of natural products across membranes [5c,11g] . Similar observations were made by Wang et al. (2014) investigating the cytotoxic effects of an expanded lycorine library, wherein there was an inverse correlation between hydrophilicity and cell penetration [11h].
The P-glycoprotein (P-gp, ABCB1) is an efflux pump of the ABC (ATP-binding cassette) superfamily of proteins involved in the transport of a huge variety of amphipathic compounds, including therapeutic drugs, natural products, peptides and lipid-like molecules in mammalian cells [11i] . It also plays a crucial physiological role in protecting cells from toxic xenobiotics and endogenous metabolites and forms a major component of the bloodbrain barrier, restricting the uptake of drugs from the small intestine [11i]. P-gp is also expressed in many human cancers where it is thought to contribute to chemotherapeutic resistance [11i] . As part of their phytochemical studies of Sprekelia formosissima and Hymenocallis x festalis, Hohmann and co-workers (2002) showed that lycorine (1) was cytotoxic to mouse L5178 lymphoma as well as its multi-drug resistant form L5178mdr with IC 50 s of 0.27 and 0.25 g/mL, respectively [10e]. Given the closeness of the results in both cell forms, lycorine was then tested for its ability to reverse multi-drug resistance in the mouse lymphoma L5178mdr cell line [10e] . In this regard, at 1 g/mL lycorine displayed a low efflux pump inhibitory effect as indicated by a fluorescence activity ratio (R) of 0.53 compared with the standard drug verapamil (R = 2.68) and was therefore deemed an unlikely substrate for the glycoprotein responsible for the efflux pump activity of the tumor cells [10e]. Furthermore, Eriksson et al. (2012) carried out a study of several CNS-acting Amaryllidaceae alkaloids and their interaction with the human multidrug resistant P-gp transporter1 in Madin-Darby canine kidney cells [11j] . Of these, the crinane analogs powelline (26) and 6-hydroxycrinamine (27) showed an interaction with the transporter (IC 50 s 300500 M), although these activities were ~100-fold less than those observed for the standard drugs verapamil and cyclosporin [11j] . Interestingly, pancratistatin (11) was shown via its Pearson correlation coefficient (0.447) to be amongst the top 26 compounds within the NCI anticancer drug screen program whose cytotoxicity profiles had the highest positive correlations with the ABCG2 transporter. ABCG2 has multiple anticancer compounds as its substrates and is known to regulate oral bioavailability and serves a protective role in the blood-brain barrier, the maternal-fetal barrier and in hematopoietic stem cells [11k] .
Another area which has attracted a fair amount of attention in the cytotoxic effects of Amaryllidaceae alkaloids is their interaction with the topoisomerases. These enzymes perform important functions in the topology of DNA, especially in regulating its overwinding or underwinding which arise as a consequence of the innate, intertwined nature of its double helical structure [12a] . Type I topoisomerase is responsible for cutting and relaxing one strand of double-stranded DNA on one hand and reannealing the loose strands on the other [12a] . By contrast, type II topoisomerase snips both strands of the DNA helix simultaneously in order to manage tangles and supercoils, acquiring the energy to drive this reaction via the hydrolysis of ATP [12a] . The clinical significance of topoisomerases has been recognized in antibacterial drug therapy, such as the broad-spectrum fluoroquinolone antibiotics which act by disrupting bacterial type II topoisomerases [12a] . Furthermore, since elevated levels of topoisomerases are detectable in rapidly proliferating cells, such as cancer cells, it has been shown that blocking this activity with suitable inhibitors could be of benefit chemotherapeutically [12b] . In this regard, the Amaryllidaceae alkaloid ungeremine (28) (also referred to as lycobetaine) has proved to be a promising target as a topoisomerase inhibitor [12be]. For example, at its growth inhibitory concentration (1100 M) in LXFL 529L human lung carcinoma cells, ungeremine also inhibited topoisomerases I and II and stabilized the covalent DNAtopoisomerase I intermediate (the so-called cleavable complex) [12b] . Furthermore, ungeremine (28) was found to be a specific topoisomerase II poison since in the presence of calf thymus DNA, pure recombinant human topoisomerase II protein was selectively depleted, whereas no depletion of topoisomerase II protein was observed [12c]. The activity of ungeremine against topoisomerases in tumor cells has been suggested to occur via its DNA-intercalating ability, especially with guanine and cytosine base pairs [12b]. In addition, ungeremine was shown to impair the activity of bacterial type 1A and IV topoisomerases [12d] . Other Amaryllidaceae alkaloids which exhibit topoisomerase-inhibiting activity include narciprimine (29) and arolycoricidine (30) (at 0.10.25 g/ml) as well as lycorine (1) against topoisomerase I, although the activity for lycorine was mild [12f,g] .
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Neutrophils are inflammatory cells which accumulate on site during the first phase of inflammation [13a] . In addition to their role in the phagocytosis of microorganisms, neutrophils also mediate inflammatory and immunological responses through a variety of protein factors, including proteolytic enzymes and cytokines [13a] . Calprotectin is one such factor abundant in the cytosol of neutrophils, which has cytostatic and cytotoxic effects against several normal and tumor cell types [13a] . Although the exact mechanism of action of calprotectin is unclear, it has been suggested that it exerts a regulatory role in inflammatory processes through its growth-inhibitory and apoptosis-inducing activities towards cells migrating into inflammatory sites [13a] . In addition, calprotectin may cause tissue damage under conditions where it exists in local body fluid for prolonged periods [13a] . Thus, the identification of targets which could regulate the adverse effects of calprotectin is an attractive prospect, of which the Amaryllidaceae alkaloids have emerged as frontrunners with significant potential for clinical exploitation [13a-c] . Initially, it was demonstrated that lycorine (1) inhibited calprotectin-induced cell death of mouse mammary carcinoma (MM46), in addition to inhibiting the suppressive effect of calprotectin on target DNA synthesis (IC 50 0.10.5 g/mL) [13b]. Furthermore, target protein synthesis is necessary for induction of cell death, and calprotectin upregulated net protein synthesis in MM46 cells [13b] . From this it was shown that although lycorine (at 1 g/mL) did not effect a marked inhibition of protein synthesis in MM46 cells without calprotectin, it did nevertheless attenuate protein synthesis that was augmented by calprotectin [13b]. In addition, narciclasine (12) inhibited calprotectin-induced cytotoxicity in MM46 cells at concentrations (IC 50 0.0010.01 g/mL) that were more than 10-fold lower than that observed for lycorine [13c] .
The inorganic free radical nitric oxide (NO) has been implicated in several physiological and pathological processes, including cancer, and is produced from the oxidation of L-arginine by the enzyme NO synthase (NOS) [14a] . The family of NO synthases is comprised of inducible NOS (iNOS), endothelial NOS (eNOS) and neuronal NOS (nNOS) [14a-d] . iNOS is particularly involved in pathological processes where there is an overproduction of NO and can be expressed in response to pro-inflammatory elements, such as interleukin-1 (IL-1), tumor necrosis factor- (TNF-) and lipopolysaccharide (LPS) in macrophages, endothelial cells and smooth muscle [14b] . The exact role of NOS in the pathophysiology of cancer is not clearly understood but it is known that high levels of NOS expression may be either cytostatic or cytotoxic to tumor cells, whereas low level activity can have the opposite effect and promote tumor growth [14a-d] . Furthermore, increased cellular NO generation could result in increased mutant p53 cell activity which would contribute to tumor angiogenesis via upregulation of VEGF (vascular endothelial growth factor) [14a] . In addition, NO may modulate tumor DNA repair mechanisms by upregulating tumor suppressor protein p53, poly-ADP ribose polymerase (PARP) and DNA-dependent protein kinase (DNA-PK) [14a] . Several alkaloids of the Amaryllidaceae have exhibited inhibitory effects on NO production in lipopolysaccharide (LPS)activated mouse peritoneal macrophages, including lycorine (1) (IC 50 2.5 M), 6-hydroxycrinamine (27) (IC 50 5.4 M), crinamine (31) (IC 50 1.8 M) and bulbispermine (32) (IC 50 24 M) [14b]. Furthermore, as described by Kang et al. (2012) lycorine also inhibited LPS-induced iNOS and COX-2 up-regulation in RAW264.7 cells through the suppression of p38 and STATs (signal transducer and activator of transcription) activation [14c] . In addition to this, narciclasine (12) exhibited potent activity against NO production in LPS-stimulated mouse RAW264 macrophages (IC 50 0.01 M) [14d].
Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric protein complex comprising the two components, HIF-1 and HIF-1. It activates the transcription of genes involved in several aspects of cancer biology, including angiogenesis, cell survival and glucose metabolism [14e]. HIF-1 is stabilized in response to hypoxia or other stimuli such as iron chelators, leading to subsequent dimerization with HIF-1[14e]. The HIF-1 complex then binds the hypoxia response element (HRE), thereby activating the expression of numerous hypoxia-response genes [14f] . Overexpression of HIF-1 in human cancers and the importance of hypoxia in the tumor microenvironment suggest that HIF-1 may have significant benefits in cancer chemotherapy [14f] . Natural product libraries provide an abundant resource for small molecule HIF-1 inhibitor targets relevant to cancer therapeutics, of which apigenin, laurenditerpenol and emetine have emerged as lead candidates [14g] . Of the Amaryllidaceae alkaloids screened for HIF-1 induced transcriptional activity in human U251 glioblastoma cells, crinamine (31) was noted for its potent dose-dependent inhibition (IC 50 2.7 M) [14g]. Crinamine, as discussed above, also inhibited NO production in LPS-activated mouse peritoneal macrophages (IC 50 1.8 M) via inhibition of iNOS [14b] . iNOS, one of many hypoxia-inducible genes, has iNOS-HRE as one of its regulatory elements which possesses a response element to a HIF-1 binding consensus sequence [14g]. These interesting findings point towards crinamine as a useful probe in understanding the relationship between cytotoxicity as well as HIF-1 and iNOS regulation [14b,g].
Tumor necrosis factor (TNF) is involved in the apoptotic pathway whereby cellular death signals are conveyed by TNF- binding to its receptor (TNF-R1) or the Fas ligand binding the Fas receptor [15a] . TNFs are a group of proinflammatory cytokines that have been implicated in tumor regression, septic shock and cachexia [15a] . Since current TNF-inhibitory clinical regimens involve only protein targets, such as Etanercept, Infliximab and Adalimumab, small-molecule drugs have been indicated as cost-effective alternatives [15b]. These include several phenolics, alkaloids, terpenes, fatty acids, sterols and retinoids [15b]. Of the various alkaloids examined, lycorine (1) and narciclasine (12) exhibited potent TNF- inhibitory effects in murine RAW264 macrophages stimulated with LPS (IC 50 s of 2.1 and 0.02 M, respectively) [14d]. Although TNF- inhibition by narciclasine was caused by nonselective inhibition of protein synthesis, lycorine was capable of inhibiting TNF- production at lower concentrations than those required to inhibit protein synthesis in macrophages [15b] . Similarly, lycorine (1) significantly inhibited LPS-induced TNF- release in RAW264.7 macrophages at a dosage of 5 M [14c].
Of the various biological mechanisms implicated in the cytotoxic effects of Amaryllidaceae alkaloids, it is their ability to induce apoptosis (or programmed cell death) selectively in cancer cells which has been at the forefront of studies directed towards understanding their mode of action. To this extent, several facets of their cytotoxic effects discussed in the preceding sections have a bearing on their apoptosis-inducing activity. The ability of tumor cells to expand profusely in number is determined by both the rates of cell proliferation and cell attrition, the latter of which is significantly fueled by the apoptotic pathway [15a] . Although acquired resistance to apoptosis is a hallmark of most cancers, the apoptotic program is installed in latent form in all cell-types and once triggered by a series of physiological signals, unfolds in a predictably sequenced manner [15a] . This includes; disruption of the cell membrane, breakdown of the cytoplasmic and nuclear skeletons, extrusion of the cytosol, degradation of chromosomes, and fragmentation of the nucleus [16a] . The apoptotic machinery is comprised of two essential components; sensors and effectors [15a,16a] . The sensors are cell surface receptors that bind survival or death factors [15a,16a] . Examples of these ligand/receptor pairs include survival signals conveyed by insulin-like growth factors IGF-1/IGF-2 through their receptor IGF-1R, and by IL-3 and its cognate receptor IL-3R [16b]. By contrast, death signals are transmitted by the Fas ligand binding the Fas receptor, and by TNF- binding TNF-R1 [16c]. Many of the signals that elicit apoptosis converge on the mitochondria which respond to proapoptotic signals by releasing cytochrome c, a potent catalyst of apoptosis [16d] . The ultimate effectors of apoptosis are the intracellular proteases known as caspases, including the gatekeeper caspases (caspase-8 and -9), which are activated by death receptor proteins such as Fas and cytochrome c [16e].
As mentioned above, Ceriotti (1967) had initially observed that the antimitotic effect of narciclasine (12) in ascites 180 sarcoma was due to adverse effects manifesting at either metaphase or preprophase [7d]. This was a significant finding, first implicating Amaryllidaceae alkaloids in cell cycle arrest of cancer cells. In plant systems, early studies on the broad bean showed that the adverse effects of lycorine (1) were manifested during cell division, particularly at the metaphase stage of mitosis [7a] . Other findings suggested that the growth inhibitory effects of lycorine in higher plants and yeasts corresponded to an increase in the number of cells at the interphase stage of cell division [7b]. Furthermore, the inhibitory effects of lycorine on cell division in onion and broad bean seedlings was shown to involve arrest at the G 1 and G 2 phases of the cell cycle [7f]. Recent studies have shown that during narciclasine-induced apoptosis in tobacco Bright Yellow-2 (TBY-2), H 2 O 2 together with antioxidant systems such as APX (ascorbate peroxidase) act as signal molecules in regulating mitochondrial activity [7g] . Subsequent mitochondrial dysfunction is manifested via a decrease in MTP (mitochondrial transmembrane potential) [7g].
The findings of Yui et al. (1998) are noteworthy in that they are amongst the first to directly associate the cytotoxic effects of Amaryllidaceae alkaloids in cancer cells to the apoptotic mode of death; in this case pertaining to the effect of lycorine (1) on MM46 cells [13b] . Several years later, Liu et al. (2004) presented the first direct evidence for the apoptotic mode of cell death induced by lycorine in human promyelocytic HL-60 leukemia [17a] . As such, lycorine inhibited the growth of HL-60 cells (IC 50 1 M) by arresting cell cycle progress at the G 2 /M phase [17a] . Furthermore, apoptotic morphological changes were indicated by the diagnostic DNA "ladder" pattern and sub-G 1 peak in cell phase distribution [17a] . At the protein level, increases in caspases-3, -8 and -9, underexpression of Bcl-2 and increase of the BaxBcl-2 ratio indicated that both caspase and Bcl-2 family proteins were involved in lycorine-mediated apoptosis in HL-60 cells [17a] .
Of the various alkaloids of the Amaryllidaceae which exhibit apoptosis inducing effects in cancer cells, it is the phenanthridones pancratistatin (11) and narciclasine (12) of the lycorine series which have attracted the most attention [5a] . This recognition also coincided with their advancement into clinical trials [11b], gathering further momentum following the discovery of several structurally-related analogs with potent and cell line selective activities (in some instances at the sub-nanomolar level) [5a] . As such, there has been broad consensus on the emergence of an anticancer drug target from this group of alkaloids [5a,11b] . Although the identification of narciclasine (12) . Similarly, pancratistatin exhibited potent in vivo cytotoxic effects against P-388 lymphocytic leukemia (T/C index of 138165% at 0.756 mg/kg) [17b] . Probes into the mechanisms behind the antiproliferative effects of these alkaloids were insightful, initially revealing that pancratistatin (11) (at 1 M) specifically targeted the mitochondria of human neuroblastoma (SHSY-5Y) cells for apoptosis induction leaving normal human diploid fibroblast (NHF) cells intact [17f] . Furthermore, pancratistatin caused activation of caspase-3 and exposure of phosphatidyl serine on the outer leaflet of the plasma membrane in human lymphoma (Jurkat) cells [17g]. These events were prior to the generation of reactive oxygen species (ROS) and DNA fragmentation, suggesting that caspase-3 and plasma membrane proteins were involved in the induction phase of apoptosis [17g]. Interestingly, while apoptotic effects were observed in cancer cells for pancratistatin dosages as low as 0.5 M, normal nucleated blood cells remained largely unaffected by such treatments [17g]. Prior to these findings, Mutsuga et al. (2002) had shown that the two pancratistatin analogs (33 and 34), at concentrations less than 1 mM, were capable of blocking cell cycle progression at the G 0 /G 1 phase resulting in apoptosis induction in rat embryonic (3Y1) fibroblasts [17h].
Narciclasine (12) . By contrast, the apoptotic process in MCF-7 cells was shown to necessitate an amplification step that is mitochondria-dependent, involving Bid processing, release of cytochrome c and caspase-9 activation [17i]. On the other hand, narciclasine (12) impaired the growth of glioblastoma multiforme by markedly decreasing mitotic rates without inducing apoptosis [17j] . Furthermore, the alkaloid also modulated the Rho/Rho kinase/LIM kinase/cofilin signaling pathway, greatly increasing GTPase RhoA activity as well as inducing actin stress fiber formation in a RhoA-dependent manner [17j]. Since glioma cells are capable of migrating through the narrow extracellular spaces in brain tissue and traveling relatively long distances, glioblastoma multiforme are elusive targets for effective surgical management [17j] . As a consequence, sufferers have a median survival expectancy of only fourteen months on the current standard treatment of surgical resection followed by adjuvant radio-and chemo-therapy [17j] . Given these dismal prognoses as well as the promising preclinical results demonstrated for narciclasine, the phenanthridones have been mooted as attractive targets in the therapy of brain cancers [17k] .
Narciclasine also exhibited good growth inhibitory values of 30100 nM against various melanoma cells through targeting Amaryllidaceae alkaloid cytotoxicity mechanisms Natural Product Communications Vol. 10 (1) 2015 177 eEF1A elongation factor [17l]. This result is significant in that melanomas are also known for poor response rates to adjuvant therapies due to their intrinsic resistance to proapoptotic stimuli [17l] . Found in abundance in eukaryote cells, the evolutionarily conserved protein eEF1A (eukaryotic translation elongation factor 1 alpha) binds to and delivers aa-tRNA (aminoacyl-tRNA) to the vacant A-site of elongating ribosomes [17l] . Furthermore, eEF1A has significant functions in actin cytoskeleton organization, cell migration, cell morphology, protein synthesis and cell death [171] . It was shown that eEF1A targeting with narciclasine (50 nM) leads to pronounced actin cytoskeleton disorganization and subsequent cytokinesis impairment, as well as protein synthesis impairment via the initiation and elongation steps [17l] . More recently, potent cytotoxic effects were described for narciclasine in HL-60 and HSC-2 (human squamous carcinoma) cells (0.018 and 0.05 M, respectively) [17m]. The apoptotic mode of cell death in this instance was indicated by characteristic morphological changes, including cell shrinkage, chromatin condensation, ladder-like fragmentation pattern for internucleosomal DNA, as well as caspase-3 activation [17m]. Another interesting mechanistic consideration for these alkaloids is that unlike other natural product derived antiproliferative agents, such as taxol, which manifest their cytotoxic effects by binding to tubulin, the phenanthridones have no effect on microtubule structure [11d] . The cytotoxic effect of the ring-C unsaturated variant narciprimine (29) in human lymphoblastic leukemia (CEM) cells (IC 50 13.3 M) was shown by to be associated with the apoptotic process, wherein a dose-dependent increase in the proportion of G 2 /M phase cells and concomitant reduction in G 0 /G 1 and S cells was observed [17n]. In terms of potency, it is noteworthy that 1-Obenzoylpancratistatin (35) has to date been identified as the most promising target of the phenanthridones, with ED 50 , GI 50 and TGI values ranging from 15.3 ng/mL in a screen involving twelve different cancers [17o]. Its best activity (GI 50 0.94 ng/mL) was seen in human pancreatic (BXPC-3) adenocarcinoma cells [17o].
Since the findings of Yui (1998) [13b] implicating Amaryllidaceae alkaloids in the apoptosis process in cancer cells, there has been widespread interest aimed at understanding their exact mode of action. Consequently, the apoptotic effects of these alkaloids have emerged as an overriding theme in studies of phenanthridone [5a,17d-e,18a] , crinane [5b,17e,18a] and lycorine [5c,17e,18a-b] alkaloids. Given that such effects were initially demonstrated for lycorine (1) [13b], many studies were subsequently carried out to explore the apoptosis-inducing activity of this alkaloid. As mentioned above, several factors, including increases in caspases-3, -8 and -9, the BaxBcl-2 ratio and G 2 /M phase cell cycle arrest were indicated as markers in lycorine-mediated apoptosis in HL-60 cells [17a] . By contrast, Zupko et al. (2009) Apart from this, McNulty and co-workers (2009) provided evidence for the dose-dependent antiproliferative effects of lycorine (1) and pseudolycorine (13) in human T-lymphoblastic leukemia (Jurkat) cells (Figure 1) [18h]. In this instance, ~90% of cells exhibited characteristic apoptotic nuclear morphology under Hoechst staining when treated over 72 h with either lycorine or pseudolycorine [18h]. This effect was seen to be less-pronounced (up to 45%) for 1-Oacetyllycorine (36), which was accessed directly from lycorine via a novel regio-chemoselective silylative strategy [18h]. In the same study, Lamoral-Theys et al. (2009) showed that lycorine exerts its in vitro antitumor activity via cytostatic rather than cytotoxic effects [18j]. Further structure-activity relationship studies by Evdokimov et al. (2011) showed that the majority of a library comprising over 30 lycorine analogs was not discriminatory between cancer cells displaying resistance or sensitivity to apoptosis, indicating that these alkaloids are able to overcome the intrinsic resistance of cancer cells to pro-apoptotic stimuli [18k]. Liu et al. (2010) Although some attempts were made early on to understand the mechanism of action of crinane alkaloids [8c,d,f] , it is only the past decade which has seen significant strides being made in this direction [5b] . Initially, Weniger et al. (1995) had suggested that the cytotoxicity of haemanthamine (14) and crinamine (31) on mouse LMTK cells (ED 50 0.5 g/mL, respectively) could be due to adverse effects manifesting on the protein of the cytoskeleton, a feature which is in abundance in these fibroblastic cells [8i] . The observations of McNulty et al. (2007) are significant in first linking crinane alkaloids to the apoptotic mode of cell death in cancer cells [19a] . In this regard, haemanthamine and crinamine induced apoptosis (90 and 95%, respectively) in rat hepatoma (5123tc) cells after 48 h with respective ED 50 values of 15 M and 12.5 M [19a] . In addition, both alkaloids were identified as selective apoptosis inducers since normal human embryonic kidney (HEK-293t) cells were unaffected by such treatments [19a] . Further insights were provided by on the mechanism of action of crinane alkaloids, whereby crinamine (31) was revealed as an apoptotic agent in Jurkat cells [19b] . After 48 h at 10 M, over 40% of these lymphoma cells were seen via Hoechst staining to display apoptotic nuclear morphology [19b] . Furthermore, it was shown via the Annexin-V/Alexa-Fluor ® 488 conjugation technique that there was a high incidence of phosphatidyl serine flipping from the inner to the outer leaflet of the plasma membrane [19b] . In addition to this, TUNEL assaying reflected considerable levels of DNA fragmentation [19b] . The Mito-Casp assay indicated a three-fold increase in caspase-3 activity after just 3 h with 10 M crinamine, while Hoechst staining showed that normal nucleated blood cells were unaffected during such treatments [19b] . There was also a destabilization of mitochondrial membrane potential, followed by leeching of cytotoxic mitochondrial content into the surrounding cytoplasm leading to the initiation of apoptotic cell death [19b] . Interestingly, necrotic cell death by crinamine was negated based on observations made with Trypan blue staining [19b] . In spite of this, haemanthamine was shown to be capable of only 22% apoptosis induction in Jurkat cells [17e,18a] .
Further studies of crinane alkaloids by McNulty et al. (2009) uncovered vittatine (38) as an apoptosis inducer in Jurkat cells, with ~70% of cells exhibiting characteristic apoptotic morphology after 24 h with a single 20 M dose, as indicated by Hoechst staining, Annexin-V binding and caspase-3 activation [19c] . Metastatic cancer cells are intrinsically resistant to apoptosis and therefore unresponsive to a large proportion of anticancer drugs, most of which function through apoptosis induction [19d] . Recent findings by are thus significant in focusing on the cytotoxic abilities of diverse Amaryllidaceae alkaloids in apoptosis-resistant as well as apoptosis-sensitive cancer cells [19e] . Of the crinane alkaloids examined, haemanthamine (14) and haemanthidine (22) were markedly active in both sensitive and resistant cell-lines with mean IC 50 values of 6.9 and 3.9 M, respectively [19e] . As such, they represent an important anticancer pharmacophore from which further structures could be generated for the therapy of gliomas, melanomas, non-small cell lung cancers and metastatic cancers which are inherently resistant to apoptosis [19e] . Related studies by Luchetti et al. (2012) showed that the crinane alkaloid bulbispermine (32) also exhibited significant inhibitory effects against the apoptosis-resistant glioma cells T98G (GI 50 9 M) and U373 (GI 50 38 M) [19f] . These authors also found that bulbispermine manifested its activity via cytostatic rather than cytotoxic effects arising out of the rigidification of the actin cytoskeleton [19f] . Apart from this, Berkov et al. (2011) revealed that crinine (2) exhibited apoptotic activity in HL-60 and MDA-MB-231 cells as shown via oligonucleosomal DNA fragmentation results [19g] .
Additional insights into the mechanism of action of crinane alkaloids was provided by based on a study of the cytotoxic effects of the rare Amaryllidaceae alkaloid distichamine (39) [17n,19h] . In a screen of five different human cancers, the adherent cell line acute lymphoblastic leukemia (CEM) was shown to be the most sensitive to treatment with distichamine (IC 50 2. (14) and haemanthidine (22) in Jurkat cells revealed that both alkaloids (at 520 M) inhibited cell proliferation and induced apoptosis via caspase activation, cell cycle arrest and attenuation of mitochondrial membrane potential [19j] . From this it was suggested that haemanthamine and haemanthidine alter cell cycle regulatory proteins depending on p16 INK4a at the G 1 /S and Ser345phosphorylated form of Chk1 at the G 2 /M checkpoint [19j] . The protective benefits provided by Amaryllidaceae alkaloids is another area which has been explored, but to a limited extent, in understanding their modes of action. In this regard, lycorine (1) was shown to offer significant hepatoprotective effects against carbon tetrachloride (CCl 4 ) induced acute toxicity in mice (at 2 mg/kg via intraperitoneal administration) as gauged by reduction in levels of ALT (alanine aminotransferase) and AST (aspartate aminotransferase) [20a] . Furthermore, lycorine (at 0.520 M) as a p21 inducer was neuroprotective against homocysteic acid (HCA) induced oxidative stress in E14.5 mouse cortical neurons [20b]. In addition, 9-O-methylpseudolycorine (40), at a concentration as low as 6.25 M, exhibited considerable neuroprotective effects against H 2 O 2 -induced cell death in SH-SY5Y neuroblastoma, with a 71% survival rate after 24 h [20c].
Further areas which have been explored to understand the biological mechanisms behind Amaryllidaceae alkaloids include: (i) antiinvasive activity; (ii) targeting of tumor-iniating cells (TICs); (iii) energy considerations; and (iv) Wnt signaling. Tumor invasion and metastasis are recognized as major causal factors contributing towards the high morbidity and mortality in cancer patients [21a,b] . Given these facts, it is surprising that mainstream therapeutic approaches remain largely focused on the primary tumor as a point for clinical intervention [21a,b] . Furthermore, while several molecular targets, including enzymes, receptors and multiple signaling pathways have been identified in metastasis drug development, a commercial anti-metastatic drug is still to reach clinical approval [21a,b] . Nonetheless, there has been some success in clinical trials with anti-angiogenic agents such as Bevacizumab (Avastin), a recombinant monoclonal antibody which inhibits VEGF-A (vascular endothelial growth factor A) [21c]. This protein functions as a chemical signal that stimulates angiogenensis in a variety of diseases, especially in cancer [21c]. Recent discoveries with Amaryllidaceae alkaloids are thus significant in highlighting the possibilities which exist in this relatively unexplored area of cancer chemotherapy [17e,18a] . In this regard, narciclasine (12), buphanamine (41) and N-methyllycorine iodide (42) at non-toxic concentrations were shown to inhibit significantly the invasion of HeLa cells into collagen type I, with only 1-4% invasion [17e,18a] . Since invasive cells secrete metalloproteinases that break down collagen type I fibers, this assay serves as an excellent model to probe in vitro modulation of cell invasion by tissue inhibitors [17e,18a] . Other efforts by Liu et al. (2012) were in support of lycorine hydrochloride (37) as a promising anti-angiogenic drug against melanomas [21d]. To this extent, lycorine hydrochloride in a dose-dependent manner suppressed formation of capillary-like structures mediated by C8161 melanoma cells in the in vitro tube formation assay [21d]. In addition, there was also a marked suppression of tumor blood vessel formation in in vivo studies of C8161-infected BALB/c nude mice [21d]. Gene expression analysis then showed that lycorine hydrochloride significantly hindered expression of VE-cadherin, while Luciferase assays indicated that this alkaloid impeded the promotory activity of the VE-cadherin gene [21d] . A significant finding from these studies was that lycorine hydrochloride did not induce apoptosis or necrosis in mouse heart and liver tissue at 715 g, doses which suppressed melanoma cell mediated vasculogenic mimicry [21d] .
Neuroblastomas are the deadliest form of extra-cranial solid tumors in children, accompanied by poor prognoses and a survival rate of less than 40% in patients older than one year [21e]. This is due to the inability of existing drugs to target tumor-iniating cells (TICs) or cancer stem cells responsible for sustaining tumor growth, metastases and relapse [21e]. In this regard, the findings of Smith et al. (2010) are highly appealing since a screen of over 4300 diverse structures from three small-molecule libraries identified the Amaryllidaceae alkaloid crinamine (31) with potent activity against TICs [21e]. In the study, crinamine selectively targeted the neuroblastoma-derived TIC line (NB TIC) with an ED 50 of 1.48 M, while sparing normal pediatric stems cells (SKPs) [21e].
Most cells have the capacity to shift their reliance on glycolysis relative to oxidative metabolism, and targeting such shifts may be useful in treating or preventing a host of diseases, including cancer [21f]. The innovative study by Gohil et al. (2010) involved screening of close to 4000 compounds for their ability to inhibit the growth of human MCH58 fibroblasts in galactose, relative to glucose-containing media [21f]. S glu/gal values, defined as the log ratio of the normalized cell number in glucose relative to galactose, were shown to be -0.16 and -0.01 for lycorine (1) and lycorine hydrochloride (37), respectively [21f]. Positive S glu/gal scores were indicative of drugs that inhibited growth in galactose, whereas negative scores were in favor of those that inhibited glycolysis or cell proliferation (since fibroblasts cultured in glucose grow more rapidly) [21f] . The S glu/gal value for lycorine hydrochloride corresponded to those for several known antineoplastic agents, including paclitaxel (-0.22) [21f].
The evolutionarily conserved Wnt/-catenin pathway performs multiple functions in embryonic development and human disease [21g]. During embryogenesis, Wnt signaling is responsible for regulation of cell fate specification, proliferation, differentiation and survival [21g] . Inappropriate regulation of the Wnt signaling pathway is linked to the progression of several diseases, including cancer, Alzheimer's disease and bone disorders [21g]. The precise control of free -catenin levels is also critical in Wnt/-catenin signaling [21g] . Furthermore, Axin is one of the key components of the pathway, and its efficient assembly into distinct complexes ensures effective transduction [21g]. While concerted efforts have been made to identify Wnt inhibitor targets, relatively few studies have focused on the discovery of Wnt activators [21g] . In this regard, a recent screen of several small-molecule compound libraries by Wang et al. (2013) led to the identification of HLY78 (43), a lycorine analog that displays remarkable synergistic effects (at 2.520 M) with Wnt ligands to activate Wnt/-catenin signaling by promoting Axin-LRP6 complex formation [21h]. From this it was suggested that such insights to Wnt/-catenin regulation could pave the way for novel therapeutic applications [21h].
Numerous structure-activity relationship (SAR) based studies have been carried out to probe the antiproliferative effects of Amaryllidaceae alkaloids, as well as to elucidate the essential elements of the active pharmacophore [5] . A consolidation of this aspect of their pharmacology is afforded in excellent reviews by Kornienko and Evidente (2008) [5a] and [5b-c]. It is apparent from such studies that, with few exceptions, the natural parent alkaloids by far superseded in activity structural variants acquired through total synthesis or semi-synthetic manipulation [5] . Furthermore, the basic phenanthridine nucleus as an essential structural element is discernible within lycorane, crinane and phenanthridone alkaloids [5] . Additional gains in activity are shown to be derived via oxygenation of the various carbocyclic ring formats innate to these alkaloids [5] . Apart from this, as indicated at various instances of this manuscript, there is convincing evidence for the selective cytotoxic effects of Amaryllidaceae alkaloids, allowing for targeted access to cancer cells with minimal effects on normal cells.
In summary, this survey offers a comprehensive overview of the various molecular mechanisms which have been elucidated in cytotoxic studies of Amaryllidaceae alkaloids. It is timely in consolidating efforts over the past five decades which have been instrumental in propelling the group onto the clinical stage of cancer chemotherapy. Overall, sixteen categories were identifiable as relevant to understanding their modes of action, several of which are inextricably linked through common targets, signaling pathways or outcomes. Of these, the identification of Amaryllidaceae alkaloids as potent and selective apoptosis-inducing agents is striking. As such, the targets with most promise are resident within the phenanthridones of the lycorine series. These factors augur well for the clinical approval of a viable commercial drug in cancer therapy.
